text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 135062-02-1 | Product Number: R0179

Repaglinide


Purity: >98.0%(T)(HPLC)
Synonyms:
  • (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic Acid
Product Documents:
200MG
59,00 €
10   16  
1G
207,00 €
1   33  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number R0179
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__2__7H__3__6N__2O__4 = 452.60 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Heat Sensitive
CAS RN 135062-02-1
Reaxys Registry Number 8238956
PubChem Substance ID 253661221
Merck Index (14) 8136
MDL Number

MFCD00906179

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 98.0 %
Melting point 131.0 to 135.0 °C
Specific rotation [a]20/D +7.0 to +10.0 deg(C=1,MeOH)
Properties (reference)
Melting Point 133 °C
Specific Rotation 9° (C=1,MeOH)
GHS
Pictogram Pictogram Pictogram
Signal Word Warning
Hazard Statements H302 : Harmful if swallowed.
H361 : Suspected of damaging fertility or the unborn child.
H362 : May cause harm to breast-fed children.
Precautionary Statements P263 : Avoid contact during pregnancy and while nursing.
P260 : Do not breathe dust.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.
Related Laws:
RTECS# DI0876305
Transport Information:
HS Number 2933399990
Application
Repaglinide: A Fast-Acting Insulin-Releasing Agent

Repaglinide, a carbamoylmethyl benzoic acid derivative, is a fast-acting insulin-releasing agent. Its mechanism of action is partly similar to that of the sulfonylureas such as glibenclamide [G0382] which binds to the sulfonylurea binding sites on pancreatic β-cells resulting in reducing blood glucose. For details, repaglinide stimulates the release of insulin from pancreatic β-cells by closing ATP-sensitive potassium channels, which results in the opening of calcium channels in the β-cells. Repaglinide is metabolized by CYP2C8 and CYP3A4 enzymes. Repaglinide is used for the treatment of type 2 diabetes. For your reference, [E0928] is a synthetic intermediate of repaglinide. (The product is for research purpose only.)

References


PubMed Literature


Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.